Browse studies

Find your next paid study

379 recruiting studies matching your filters

Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fr…

Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction

Estimated

~$10 – $8,750

35Pharma IncNCT07123779

Phase 2

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension …

Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Estimated

~$10 – $8,750

OrphAI TherapeuticsNCT05798923

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with …

Pulmonary HypertensionInterstitial Lung Disease

Estimated

~$10 – $8,750

Insmed IncorporatedNCT07179380

Observational

Aligning Clocks: Time-Restricted Eating to Improve Cardiovascular Health in Hypertensive Older Adults Who Skip Breakfast

This study will examine whether eating earlier in the day within a consistent 8-hour eating window can improve heart and blood vessel health in older adults wi…

HypertensionBreakfast Skipper

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT07634926

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-…

OverweightPrediabetic StatePrehypertension+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07794579

Phase 1

A Phase 1/2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension

This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hyperte…

Primary Open Angle Glaucoma (POAG)Ocular Hypertension (OHT)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07675824

Diabetes and Heart Disease Risk in Blacks

It is unknown if obesity contributes to the development of heart disease in African American men and women. This study was created to determine whether there …

Cardiovascular DiseasesDiabetesObesity+1 more

Estimated

~$10 – $675

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00001853

Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences o…

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionScleroderma Associated Pulmonary Arterial Hypertension+1 more

Estimated

~$10 – $750

Vanderbilt University Medical CenterNCT01884051

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of th…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07318597

Phase 3

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination wi…

Chronic Kidney Disease and Hypertension

Estimated

~$10 – $7,500

AstraZenecaNCT06742723

Observational

MH-Rx Study: Comprehensive and Multi-Level Medication Therapy Management and Non-Medical Health Related Needs Targeted Intervention Model for Maternal Health Outcomes. (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)

This randomized controlled trial will evaluate whether adding Community Health Worker (CHW)/Social Worker (SW)-led support for non-medical health related needs…

Hypertensive Disorders of PregnancyChronic Hypertension in PregnancyGestational Hypertension

Estimated

~$10 – $6,250

Texas Southern UniversityNCT07842341

Phase 1

Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One prim…

Chronic Obstructive Pulmonary DiseasePulmonary Artery HypertensionHeart Failure+1 more

Estimated

~$10 – $7,500

D. Walter WrayNCT02966665